Licensing status

Publication and contact information


Prostate cancer

UDP glucuronosyltransferase 2 family polypeptide B15 (UGT2B15)

Patient and cell culture studies suggest activating UGT2B15 could help treat prostate cancer. In samples from patients with prostate cancer receiving androgen deprivation therapy, UGT2B15 levels were higher than those in patients not receiving the therapy. In cultured prostate cancer cell lines, androgen receptor (AR) antagonists led to an AR-dependent decrease in UGT2B15 expression and activity compared with no treatment. Also in the cells, UGT2B15 knockdown decreased the antiproliferative effects of AR antagonists compared with no knockdown. Next steps include finding selective activators of UGT2B15 and generating transgenic mouse models expressing human UGT2B15.

SciBX 6(46); doi:10.1038/scibx.2013.1318
Published online Dec. 5, 2013

Unpatented; licensing status not applicable

Grosse, L. et al. Cancer Res.; published online Oct. 11, 2013;
Contact: Olivier Barbier, Universite Laval, Quebec City,
Quebec, Canada